Recent reports have shown that PrPc decreases the extracellular levels of amyloid oligomers, which indicates that it might be a target for putative therapies in Alzheimer's disease [58]. The gene discussed is PRNP; the disease is early-onset autosomal dominant Alzheimer disease.